RCT: Efficacy of HD201 vs. referent Trastuzumab in patients With ERBB2-positive breast cancer treated in the neoadjuvant setting.
9 Mar, 2022 | 08:22h | UTC
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1499791783735271426
Open access